



Improving Data Collection Quality and Completeness for SACT in Prostate Cancer

Case Study: The Royal Marsden NHS Foundation Trust

Background

The NPCA State of the Nation Report 2025 found that 47% of men newly diagnosed with metastatic hormone-sensitive prostate cancer received systemic treatment intensification therapy within 12 months of diagnosis in 2022 in England.



The Royal Marsden NHS Foundation Trust (RMH) was identified as a potential negative outlier following the NPCA Outlier Process 2025.

Identification

Evaluation

The RMH team identified errors with routine SACT data submission of oral hormonal therapies (e.g. Abiraterone, Apalutamide, Enzalutamide, etc.).



The Pharmacy and Informatics teams at the RMH worked closely together to retrospectively upload missing SACT data to the National Disease Registration Service (NDRS) which led to significant improvements in SACT data quality and completeness.

Solution

Local QI Plan

- Transition to EPIC EPR system (March 2023)
- Implementation of Microsoft Power BI to develop an internal data dashboard
- Monthly SACT board meetings

